RxDoctor Payments Data

Kelly Ratz

Psychiatric/Mental Health · Fenton, MONPI 1114328275

Payments from drug & device makers

$3,856in general payments, 2019–2025

Across 203 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$481
  • Teva Pharmaceuticals USA, Inc.$401
  • Sunovion Pharmaceuticals Inc.$386
  • Alkermes, Inc.$340
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$309
  • plus $728 from 10 others

What the payments were for

  • Food & beverage$3,80999%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,856 in reported general payments places this provider in the 80th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$4,827
Medicare patients
24
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate65$243,907
VraylarCariprazine Hcl51$76,926
AustedoDeutetrabenazine11$66,599
TrintellixVortioxetine Hydrobromide37$17,854
Lurasidone Hcl52$11,443
Aripiprazole57$7,689
Atomoxetine Hcl29$3,529
Hydroxyzine Hcl146$3,116
Quetiapine Fumarate154$3,059
Duloxetine Hcl106$2,977
Asenapine Maleate23$2,859
Paliperidone ErPaliperidone17$2,202
Buspirone Hcl137$2,078
Bupropion XlBupropion Hcl62$1,545
Quetiapine Fumarate ErQuetiapine Fumarate16$1,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$39$243,90765 claims
AbbVieVraylar$1,212$76,92651 claims
Teva Pharmaceuticals USA, Inc.Austedo$401$66,59911 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$242$17,85437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Fenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →